drugset / Trial / NCT02897349

Linagliptin Add-on to Insulin Background Therapy

NCT02897349

Phase 3 Completed 206 enrolled Boehringer Ingelheim Eli Lilly and Company · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the efficacy and safety of linagliptin compared to placebo when added on to insulin therapy alone or in combination with metformin in Chinese patients with type 2 diabetes mellitus with insufficient glycaemic control

Timeline

Start
2016-09-30
Primary completion
2019-01-11
Completion
2019-01-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Linagliptin Small molecule Oral
Background Insulin Protein / enzyme biologic
Background Metformin Small molecule